Konica Minolta Precision Medicine Japan

GenMine Labs (formerly Konica Minolta Precision Medicine Japan) is a precision medicine company specializing in advanced genetic testing and diagnostic services. The company provides the GenMineTOP Cancer Genome Profiling System, a multi-panel test that analyzes both DNA and RNA to identify gene mutations and expression levels. Originally established as a subsidiary of Konica Minolta to integrate technologies from Ambry Genetics and Invicro, it was acquired by SB TEMPUS (a SoftBank/Tempus AI joint venture) in 2025. The company serves pharmaceutical companies, academic institutions, and medical centers by providing biomarker identification, clinical trial support, and diagnostic tools to optimize personalized patient care.